Study of obicetrapib and ezetimibe for diabetes and metabolic syndrome
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a combination medication (obicetrapib plus ezetimibe) taken daily to lower cholesterol and triglycerides in people with type 2 diabetes or metabolic syndrome who are already on standard cholesterol treatment. It may help reduce heart risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes or metabolic syndrome (including high triglycerides and at least 2 risk factors like high blood pressure or low HDL).
- Your fasting LDL cholesterol is 70 mg/dL or higher.
- Your fasting triglycerides are between 150 and 400 mg/dL.
- You are already on stable cholesterol-lowering medication (like a statin).
- Your kidney function is good enough (eGFR 15 or more).
- You do not have severe heart failure, uncontrolled high blood pressure, or active liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two new medicines—obicetrapib and bempedoic acid—to see which one better lowers cholesterol in people whose cholesterol remains high despite taking standard medications. If your cholesterol isn't controlled well enough with current drugs, this trial may help you access an experimental treatment.
This trial tests whether a new cholesterol-lowering drug, obicetrapib, affects antioxidant levels in the blood and HDL (good cholesterol) particles. It is currently for healthy volunteers only.
This study tests two new drugs, alone and together, to lower a type of cholesterol called Lp(a) that increases heart disease risk. You may qualify if you have high Lp(a) and your LDL cholesterol is still high despite current treatment.
This trial tests a medicine called Ezefeno to see if it helps lower cholesterol in people with type 2 diabetes who are already on statins. It may be an option if you have high triglycerides and other heart risk factors.
This study watches how well a combination cholesterol medication (pitavastatin and ezetimibe) works in people who have high cholesterol and metabolic syndrome (a cluster of health issues including high blood pressure, blood sugar, and cholesterol). You'll be monitored over time to see if the medication helps and is safe for you.
This trial tests if pitavastatin alone or with ezetimibe affects blood sugar differently than atorvastatin in people who have heart or blood vessel disease and metabolic syndrome but do not have diabetes.
Hear when a new Type 2 Diabetes (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.